A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

Several PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity. We have recently reported promising efficacy results treating chronic lymphocytic leukemia (CLL) patients with combination therapy with the PI3K...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadi, Deepti, Griffith, Alec, Tyekucheva, Svitlana, Wang, Zixu, Rai, Vanessa, Vartanov, Alexander, Thrash, Emily, Fernandes, Stacey M, Lehmberg, Timothy Z., Lee, Brandon, Martindale, Stephen P, Machado, John-Hanson, Odejide, Oreofe, Armand, Philippe, Fisher, David C., Arnason, Jon, Davids, Matthew S., Lederer, James A, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891037/
https://www.ncbi.nlm.nih.gov/pubmed/34743191
http://dx.doi.org/10.1038/s41375-021-01441-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891037/
https://www.ncbi.nlm.nih.gov/pubmed/34743191
http://dx.doi.org/10.1038/s41375-021-01441-9

Ejemplares similares